Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 3:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 153 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breathing, Mouth Clear all
Completed No phase listed Observational

Computational Modeling of Cleft Lip Nasal Deformity and Assessment of Nasal Function and Treatment Outcomes

NCT04150783
View directory record Official record
Conditions
Cleft Lip and Nose, Nasal Obstruction
Interventions
Surgical repair for nasal obstruction
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 12, 2026, 3:50 PM EDT
Completed Phase 4 Interventional

A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus

NCT00367445
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Inhaled Human Insulin (Exubera), Insulin Glargine (Lantus)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Oct 12, 2026, 3:50 PM EDT
Completed No phase listed Observational

Evaluating Deep Breathing in Health Participants Using a Device Called Impulse Oscillometry

NCT05085795
View directory record Official record
Conditions
Breathing, Mouth, Lung Function Decreased
Interventions
Impulse Oscillometer
Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
20 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 12, 2026, 3:50 PM EDT
Completed No phase listed Observational

Evaluating Instrumentation for Dental Devices Used in Treating Sleep Apnea

NCT02056327
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
A novel monitoring suite of sensors will be inserted into the standard oral device.
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 12, 2026, 3:50 PM EDT
Completed Phase 3 Interventional Results available

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients

NCT01533922
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo, Tiotropium, Olodaterol, Tiotropium + Olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Torrance, California • Hartford, Connecticut • Livonia, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2015 · Synced Oct 12, 2026, 3:50 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)

NCT00883129
View directory record Official record
Conditions
Scleroderma, Interstitial Lung Disease
Interventions
Mycophenolate mofetil, Cyclophosphamide, Placebo
Drug
Lead sponsor
Michael Roth
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 12, 2026, 3:50 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

NCT05934526
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, Seralutinib, Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
GB002, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
50
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 12, 2026, 3:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Oral Hymecromone and Hyaluronan Synthesis

NCT02780752
View directory record Official record
Conditions
Healthy, Respiratory Disease
Interventions
hymecromone
Drug
Lead sponsor
Paul Bollyky
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 12, 2026, 3:50 PM EDT
Terminated Phase 3 Interventional Results available

Management of Recurrent Croup

NCT01748162
View directory record Official record
Conditions
Croup
Interventions
Fluticasone, Prednisolone IF needed
Drug
Lead sponsor
University of Michigan
Other
Eligibility
6 Months to 15 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 12, 2026, 3:50 PM EDT
Completed Phase 2 Interventional Results available

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

NCT02871778
View directory record Official record
Conditions
Primary Ciliary Dyskinesia
Interventions
VX-371, Hypertonic Saline, Placebo (0.17% saline), VX-371 + HS, Ivacaftor
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
12 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 12, 2026, 3:50 PM EDT
Recruiting Not applicable Interventional

The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study

NCT05988385
View directory record Official record
Conditions
Obstructive Sleep Apnea, Cognitive Decline
Interventions
Positive airway pressure, Oral appliance therapy, Positional therapy
Device
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
55 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Tucson, Arizona • New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 12, 2026, 3:50 PM EDT
Completed Phase 3 Interventional Results available

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

NCT01696058
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo matching Olodaterol, Olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
94
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 12, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Results available

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

NCT02889809
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate, Placebo, Montelukast, Short Acting Beta 2 Agonist
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 9 Years
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
18
States / cities
Little Rock, Arkansas • Huntington Beach, California • Homestead, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 12, 2026, 3:50 PM EDT
Completed Phase 2 Interventional Results available

Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.

NCT03257995
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol maleate, Indacaterol acetate, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
North Dartmouth, Massachusetts • St Louis, Missouri • Skillman, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 12, 2026, 3:50 PM EDT
Completed Phase 3 Interventional Results available

Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)

NCT01964352
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, placebo, olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
20
States / cities
Wheat Ridge, Colorado • Clearwater, Florida • Panama City, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 12, 2026, 3:50 PM EDT
Recruiting Phase 3 Interventional

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

NCT06274801
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Seralutinib, Gereic Dry Powder Inhaler
Drug · Device
Lead sponsor
Gossamer Bio USA, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
33
States / cities
Fresno, California • Los Angeles, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 12, 2026, 3:50 PM EDT
Terminated Phase 1 Interventional

Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function

NCT05625347
View directory record Official record
Conditions
Obstructive Pulmonary Function, Restrictive Pulmonary Function
Interventions
single dose (100 mg) of ASA, single dose (162 mg) of non-enteric-coated chewable aspirin tablets
Drug
Lead sponsor
Vectura, Inc.
Industry
Eligibility
40 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
4
States / cities
Orlando, Florida • Winter Park, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 12, 2026, 3:50 PM EDT
Recruiting Not applicable Interventional

Severe Label Expansion for EVO Products Trial

NCT07090395
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
EVO Sleep and Snore Device
Device
Lead sponsor
ProSomnus Sleep Technologies
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 12, 2026, 3:50 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

NCT05392192
View directory record Official record
Conditions
Chronic Cough
Interventions
ADX-629, Placebo
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
14
States / cities
San Diego, California • San Jose, California • Hollywood, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 12, 2026, 3:50 PM EDT
Completed Not applicable Interventional Results available

Chlorhexidine Gluconate Oral Care for Adults Experiencing Trauma

NCT01382446
View directory record Official record
Conditions
Ventilator Associated Pneumonia
Interventions
Chlorhexidine gluconate, Toothpaste
Drug · Other
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 12, 2026, 3:50 PM EDT
Recruiting Phase 2 Interventional

Study to Examine the Effect of Silicone Mouth Tape on Snoring and Mild Sleep Apnea.

NCT06587256
View directory record Official record
Conditions
Mild Obstructive Sleep Apnea, Snoring
Interventions
Mouth Tape
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 12, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Results available

Isopropyl Alcohol vs Ondansetron for Nausea in the Emergency Department

NCT02760069
View directory record Official record
Conditions
Nausea
Interventions
Inhaled isopropyl alcohol, Oral ondansetron, Inhaled normal saline, Oral placebo
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 12, 2026, 3:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

NCT01191723
View directory record Official record
Conditions
Healthy
Interventions
MAP0004, Inhaler Placebo, Moxifloxacin, Placebo Capsule
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 12, 2026, 3:50 PM EDT
Terminated No phase listed Observational

Novel Technique for Face Mask Ventilation

NCT01946464
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 26, 2016 · Synced Oct 12, 2026, 3:50 PM EDT